Trial Profile
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2021
Price :
$35
*
At a glance
- Drugs NSA 789 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 17 Aug 2021 Status changed from discontinued to completed.
- 22 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.